SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to significant community anticipation surrounding its pivotal role in next-generation AI data centers, particularly with its advanced power solutions crucial for high-density computing infrastructure. The company's upcoming participation in a key industry conference is fueling discussions, as many investors speculate on potential news catalysts and the high short interest driving a prospective squeeze.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a high-profile meeting between its CEO and President Trump, where Trump publicly praised the company's US-based chip manufacturing and the profitable government investment. This has sparked intense community discussion, with many anticipating significant partnerships and a successful foundry turnaround driven by new technologies, while others remain cautious, attributing the stock's momentum primarily to political influence rather than fundamental shifts.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed following its acquisition of a mobile analysis facility that will dramatically expedite rare-earth assay results from its key Greenland project. This development aligns with intense geopolitical focus on Greenland's critical mineral potential, as the community eagerly anticipates outcomes from high-level U.S.-Danish-Greenlandic meetings and speculates on CRML's strategic importance in securing Western rare-earth supply chains.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is trending due to the undeniable success of its new Kennesaw, GA location, which is driving significant sales and validating the brand's expansion potential outside its home market. The community is actively debating the company's deep undervaluation and high short interest, fueled by anticipation of a new CEO announcement and potential relief from fluctuating beef prices.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal ($PYPL) is trending due to a stark divergence between its perceived value and market performance, fueling intense community debate. While recent analyst downgrades and a challenging price action frustrate many, bulls emphasize strategic AI partnerships, significant buybacks, and potential upside from proposed credit card rate caps for its BNPL offerings, asserting the stock is fundamentally undervalued despite persistent skepticism.

Monero

Monero (XMR) is trending strongly as its community champions it as the 'king of privacy' and the 'real Bitcoin' amid growing global discourse on digital anonymity. Despite discussions around regulatory scrutiny of privacy tokens, XMR demonstrates significant momentum, with users emphasizing its superior decentralization and robust technology over alternatives.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is experiencing significant volatility and a pre-decision sell-off as the market reacts to the FDA's recent request for additional clarification on the clinical benefit of FILSPARI for the FSGS indication. While some investors view this information request as a strong signal for a potential Complete Response Letter or delay, leading to sharp declines, others are actively buying the dip, viewing the steep decline as an overreaction given the drug's strong efficacy and high unmet need. The community is actively debating whether this is a common regulatory step or a fundamental setback for a therapy poised to become the first approved treatment for FSGS, a rare kidney disorder.

Ribbon Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 17, 2024 and is headquartered in Tokyo, Japan.

Ribbon Acquisition Corp. - Ordinary Shares - Class A

Ribbon Acquisition Corp. is attracting significant attention as a 'fresh SPAC,' with community discussions highlighting a recent vote and anticipation of a catalyst. Many are observing its small float and perceived low risk near its NAV, drawing comparisons to other SPACs that have seen rapid movements.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending due to its exceptionally active and fiercely loyal community, which is relentlessly building a permissionless brand with numerous real-world products and initiatives. The conversation centers on its evolution from a meme to a robust brand, showcasing significant IRL efforts and a strong conviction for long-term growth across multiple blockchains. Enthusiasts are actively encouraging early participation, emphasizing dedication to building and a unique value proposition in the crypto space.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is at the forefront of discussion following groundbreaking Phase 1 data for CTX310, showcasing deep and durable reductions in cholesterol and triglycerides from a single gene-editing dose, igniting community enthusiasm for its potential to revolutionize heart disease treatment. Investors are also eagerly anticipating pipeline updates, including for Type 1 Diabetes and Casgevy's market uptake, while persistent rumors of a significant buyout by a major pharmaceutical company continue to fuel speculation and highlight the stock's considerable short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% - Here's Why

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% - Should You Sell...

Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Below Fifty Day Moving Average - Here's Why

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Passes Below Fifty Day Moving Average - Here's What Happened...

Voya Investment Management LLC Trims Position in Ocular Therapeutix, Inc. $OCUL

Voya Investment Management LLC reduced its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 36.7% during the 3rd quarter, according to its most recent filing with the Securities...

Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL

Assenagon Asset Management S.A. decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 76.5% during the 3rd quarter, according to the company in its most recent filing with...

Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving Average - What's Next?

Ocular Therapeutix (NASDAQ:OCUL) Shares Cross Above 50-Day Moving Average - Should You Sell...

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.3% - What's Next?

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 4.3% - What's Next...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, Marketbeat.com...

Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of Ocular Therapeutix in a research report on Tuesday...

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Ocular Therapeutix Inc (NASDAQ: OCUL) stock surged after announcing plans to expedite FDA submission for its wet AMD treatment.read more...

Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Ocular Therapeutix in a report on Monday...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

Traders are actively discussing complex options strategies, including bull put credit spreads and calls, to position around expected volatility and potential price swings.

Anticipation is high for upcoming top-line results from the SOL-1 study, which could provide a major catalyst if it demonstrates superiority over existing treatments.

Significant daily trading volume and pronounced price movements suggest intense short-term buying and selling, alongside chatter about accumulation efforts.

OCUL
Ocular Therapeutix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCUL News

OCULOcular Therapeutix Inc